//Content pusher
Amyvid logo
Register Your Profile

You are registering for information that is intended for US Health Care Professionals only. By registering at this site, you certify that you are a licensed US Health Care Professional. Your selected e-mail address and password will allow you to opt in or out of future Amyvid communications.

Fill in all required fields and click the REGISTER NOW button.

First Name
Last Name
Street Address 1
Street Address 2 (Optional)
City
State Zip
Primary Speciality
State Licensed In (Optional) State License Number (Optional)
E-mail Address
Confirm E-mail Address
Password (Must be 8 characters, 1 numeric)
Confirm Password

For additional information about Lilly and other products, visit Lilly.com

Important: The information you provide in this form will be used in accordance with the Lilly Privacy Statement. You may be contacted by any of the channels provided (ie, phone, e‑mail) and that contact may come from Lilly USA, a third party operating on behalf of Lilly USA, or an Alliance Partner.

By registering at this product site, you are indicating that you wish to receive information regarding this product, related training programs, and other pertinent information. Lilly's intent is to only provide information to health care professionals who would likely be treating patients within the FDA‑approved indications for this product. If you have selected a specialty that is outside of the appropriate patient population, per the FDA‑approved indications for this product, you may not receive information about this product.

READ MORE
INDICATION AND IMPORTANT SAFETY INFORMATION FOR AMYVID (Florbetapir F 18 Injection)
INDICATIONS AND USAGE

Amyvid is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline.

A negative Amyvid scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient's cognitive impairment is due to AD. A positive Amyvid scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Amyvid is an adjunct to other diagnostic evaluations.

Limitations of Use:
  • A positive Amyvid scan does not establish a diagnosis of AD or other cognitive disorder
  • Safety and effectiveness of Amyvid have not been established for:
    • Predicting development of dementia or other neurologic condition
    • Monitoring responses to therapies

Amyvid for intravenous use is supplied in multidose vials containing
500-1900 MBq/mL Florbetapir F 18.

IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS

Risk for Image Misinterpretation and Other Errors

  • Errors may occur in the Amyvid estimation of brain neuritic plaque density during image interpretation
  • Image interpretation should be performed independently of the patient's clinical information. The use of clinical information in the interpretation of Amyvid images has not been evaluated and may lead to errors. Other errors may be due to extensive brain atrophy that limits the ability to distinguish gray and white matter on the Amyvid scan as well as motion artifacts that distort the image
  • Amyvid scan results are indicative of the brain neuritic amyloid plaque content only at the time of image acquisition and a negative scan result does not preclude the development of brain amyloid in the future

Radiation Risk

  • Amyvid, similar to other radiopharmaceuticals, contributes to a patient's overall long‑term cumulative radiation exposure. Long‑term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to protect patients and health care workers from unintentional radiation exposure
MOST COMMON ADVERSE REACTIONS
  • The most common adverse reactions reported in clinical trials were headache (1.8%), musculoskeletal pain (0.7%), blood pressure increased (0.7%), nausea (0.7%), fatigue (0.5%), and injection site reaction (0.5%)

Please see Full Prescribing Information for Amyvid.

AM HCP ISI 10JAN2014